Survey of the in vitro susceptibility of Helicobacter pylori to antibiotics in France: Preliminary results

Broutet, Nathalie; Guillon, Florence; Sauty, Evelyne; Lethuaire, Denis; Mégraud, Françis

doi:10.1016/s0016-5085(98)80328-4

Cited by 24 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The reported prevalence of nitroimidazole resistance is highly variable and has increased over time. In developing countries resistance rates are reported to be 80–90%, while in most western countries resistance rates vary from 10 to 56% 13 –15 …”

Section: Discussionmentioning

confidence: 99%

A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication rates

Houben

Beek

Hensen

et al. 1999

Aliment Pharmacol Ther

311

266

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication rates

Houben

Beek

Hensen

et al. 1999

Aliment Pharmacol Ther

311

266

View full text Add to dashboard Cite

show abstract

“…It is more likely that this difference is a consequence of a more lax policy regarding antibiotic use in southern and eastern Europe. A large active survey of H. pylori resistance, performed in France in 1997, also showed 14% primary resistance to clarithromycin [19].…”

Section: Discussionmentioning

confidence: 99%

Ranitidine Bismuth Citrate Can Help to Overcome Helicobacter pylori Resistance to Clarithromycin In Vivo

Mégraud

Roberts²,

Williamson³

2000

Helicobacter

Self Cite

View full text Add to dashboard Cite

show abstract

“…Similarly, the prevalence of resistance in 128 H. pylori strains isolated in 2004-2005 to FLQ (ciprofloxacin MIC > 1 mg/L) was 17% (22 strains) [14], while for CLA the pretreatment and posttreatment prevalence of resistance were 19% (23/123) and 69% (9/13), respectively [15]. This CLA resistance was relatively high compared to that reported as the national prevalence of resistance in France, which stood at 13% [16]. Results of a study of 2204 patients in Europe showed that H. pylori resistance rates were 16% to CLA, 14% to levofloxacin, and 35% to metronidazole.…”

Section: Introductionmentioning

confidence: 99%

Helicobacter pylori from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool

Angol

Ocama

Kirabo

et al. 2017

BioMed Research International

View full text Add to dashboard Cite

Background Around 70–90% of peptic ulcer disease (PUD) is due to Helicobacter pylori and requires treatment with antimicrobials to which these bacteria are susceptible. Common H. pylori diagnostic tests do not provide drug susceptibility data. Using the GenoType HelicoDR PCR test designed for gastric biopsies for simultaneous detection of H. pylori and its resistance to clarithromycin (CLA)/fluoroquinolones (FLQ), we present evidence for stool as an optional test specimen and also provide data on prevalence of H. pylori resistance to CLA and FLQ in Uganda. Methods Stool from 142 symptomatic PUD patients at three hospitals in Kampala was screened for H. pylori using a rapid antigen test. The GenoType HelicoDR test was run on all H. pylori antigen positives to determine PCR positivity and resistance to CLA/FLQ. Results Thirty-one samples (22%) were H. pylori antigen positive, and 21 (68%) of these were H. pylori PCR positive. Six of the 21 (29%) were resistant to CLA and eight to FLQ (42%), while two gave invalid FLQ resistance results. Conclusion Stool is a possible specimen for the GenoType HelicoDR test for rapid detection of H. pylori and drug resistance. In Uganda, Helicobacter pylori is highly resistant to CLA and FLQ.

show abstract

Survey of the in vitro susceptibility of Helicobacter pylori to antibiotics in France: Preliminary results

Cited by 24 publications

References 0 publications

A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication rates

A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication rates

Ranitidine Bismuth Citrate Can Help to Overcome Helicobacter pylori Resistance to Clarithromycin In Vivo

Helicobacter pylori from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool

Contact Info

Product

Resources

About